Cryoport Reports Second Quarter 2026 Financial Results

EarningsPositive

AI Analysis

Summary

Cryoport reported Q2 2026 revenue of $49.0 million, representing 8% year-over-year growth, with Life Sciences Services revenue increasing 15% and BioStorage/BioServices revenue growing 25%. The company is supporting 779 global clinical trials and 22 commercially approved cell and gene therapies as of June 30, 2026.

Financial Highlights

Revenue

$49.0 million

Importance:5/10

Sentiment:

0.60

earningsrevenue growthcell and gene therapyclinical trialslife sciences services

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Biotech on August 6, 2026 8:05 PM

Read Original